Chauvet B, Fignon A, Calais G, Lansac J, le Floch O
Clinique d'Oncologie et Radiothérapie, Centre Hospitalier Régional Bretonneau, Tours.
J Gynecol Obstet Biol Reprod (Paris). 1989;18(4):526-32.
In order to better assess the place of radiotherapy in the treatment of ovarian carcinoma, the length of survival in 44 patients treated with irradiation has been examined. 44 patients, with nil or minimal (less than 2 cm) residual disease, were found among 92 patients with invasive ovarian carcinoma treated consecutively in our center from 1976 to 1986. Treatment included laparotomy for 42 patients. Debulking surgery was complete in 9 stage I and 10 stage II patients. Those patients also received abdominopelvic (16 cases) or pelvic (3 cases) irradiation. Residual tumour was left in the 25 remaining patients (2 with stage IIc, 18 with stage III, and 5 with stage IV) who further underwent various regimes of polychemotherapy (9 without and 16 with cisplatin) followed by second-look laparotomy. 25 patients had no (8 patients) or minimal (17 patients) residual disease after this second laparotomy and they underwent abdominopelvic irradiation. Overall 3-year survival was 68%, 3-year survival was 80% for stage I and II patients treated by radiotherapy after initial complete debulking surgery, and 58% for advanced stages treated by radiotherapy after chemotherapy and second-look laparotomy, 3-year survival was 71% for 18 patients with stage III. Tolerance for irradiation was significantly decreased after chemotherapy and this prevented a complete dose being delivered to 32% of the patients. A late severe complication was noted in only one case. For stage I or II our results are close to those already published by others.(ABSTRACT TRUNCATED AT 250 WORDS)
为了更好地评估放射治疗在卵巢癌治疗中的地位,我们对44例接受放疗的患者的生存时长进行了研究。在1976年至1986年期间于本中心连续接受治疗的92例浸润性卵巢癌患者中,发现了44例残留病灶为零或极小(小于2厘米)的患者。42例患者接受了剖腹手术。9例I期和10例II期患者的肿瘤细胞减灭术完成。这些患者还接受了腹盆腔放疗(16例)或盆腔放疗(3例)。其余25例患者(2例IIc期、18例III期和5例IV期)残留有肿瘤,他们进一步接受了各种多药化疗方案(9例未使用顺铂,16例使用顺铂),随后进行了二次剖腹探查术。25例患者在第二次剖腹手术后无残留病灶(8例)或残留病灶极小(17例),他们接受了腹盆腔放疗。总体3年生存率为68%,初始肿瘤细胞减灭术后接受放疗的I期和II期患者3年生存率为80%,化疗和二次剖腹探查术后接受放疗的晚期患者3年生存率为58%,18例III期患者的3年生存率为71%。化疗后放疗耐受性显著降低,这使得32%的患者无法接受完整剂量的放疗。仅1例出现晚期严重并发症。对于I期或II期患者,我们的结果与其他已发表的结果相近。(摘要截选至250字)